首页/癌基因/EGFR/ AMPLIFICATION EGFR编码的蛋白是一种跨膜糖蛋白,也是表皮生长因子受体家族中的一员,该家族包括HER1(erbB1,EGFR)、HER2(erbB2,NEU)、HER3(erbB3)及HER4(erbB4),也属于受体酪氨酸激酶家族。EGFR作为细胞表面蛋白可与配体如表皮生长因子(EGF)结合,EGFR可被激活,由单体转化为二聚体以及发生自体...
参考文献: Wang Z, Huang C, Fan W, Sun S, Li K, Liu X, Pu J, Zhang G, Li X. Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy. Front Oncol. 2024 Mar 25;14:134728...
EGFR 扩增驱动非小细胞肺癌脑转移:细胞黏附负调控机制的关键发现 《Biological Procedures Online》:Negative Regulation of Cell Adhesion as a Driver of Brain Metastasis in NSCLC Patients with EGFR Amplification 编辑推荐: 肺癌脑转移预后差,治疗手段有限。为探究其机制,研究人员对比肺癌与脑转移瘤组织的二代靶向测...
EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?Prognostic factorLong term survivalGlioblastomaIDHEGFRKi67p53Once again the main difference in terms of OS in GBM is shown in a EOR and in Age. To our knowledge...
英文标题:Vebreltinib Plus PLB1004 In EGFR-Mutated, NSCLC with MET Amplification or MET Overexpression Following EGFR-TKI 中文标题:伯瑞替尼联合PLB1004治疗EGFR-TKI治疗后出现MET扩增或过表达的EGFR突变NSCLC患者 讲者:李玮(上海市...
[12]MINARI R, BORDI P, LA MONICA S, et al. Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC [J]. J Thorac Oncol, 2018, 13(6): e89-e91.[13]RIBEIRO M, KNEBEL F H, BETTONI ...
MET扩增是EGFR突变非小细胞肺癌(NSCLC)对EGFR抑制剂的常见耐药机制。多项试验显示,EGFR和MET抑制剂(EGFRi/METi)联合治疗可取得令人鼓舞的结果。然而,MET扩增的定义并不一致,通常包括多体和真扩增(true amplification,又称局部扩增)。这是一项多中心、真实世界分析,针对EGFR抑制剂治疗疾病进展和MET拷贝数增加(CNG)的患...
[4]Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43. [5]Ramalingam SS, Cheng Y, Zhou C, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary ...
这样可以让靶向药物用的更长一些。参考文献：Knebel FH ,et al., Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC，Lung Cancer. 2017 Jun;108:238-241.
[12]Kim Y,et al. EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance. Oncologist. 2024 May 6:oyae076. 审批编号:CN-139972 有效期至:2025-7-25 * 此文...